Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dr Reddy’s Laboratories ( (RDY) ) has provided an announcement.
On September 17, 2025, Dr. Reddy’s Laboratories announced the transfer of 20.58% of its equity shares by its promoters to private family trusts. This move, involving the transfer of shares by Satish Reddy Kallam and G V Prasad to the VSD Family Trust and GVP Family Trust respectively, is part of a succession planning strategy. The transfer, which was facilitated by an exemption from SEBI, does not alter the management or control of the company, ensuring stability for stakeholders.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories exhibits strong financial health and strategic growth initiatives, which are offset by challenges in the U.S. generics market and declining gross profit margins. The technical analysis suggests stability, while the valuation is fair. The earnings call provided a mixed outlook, balancing growth with market challenges.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent player in the pharmaceutical industry, based in Hyderabad, India. The company is known for its wide range of pharmaceutical products and services, focusing on generic drugs and active pharmaceutical ingredients, with a significant presence in both domestic and international markets.
Average Trading Volume: 1,214,243
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.39B
See more insights into RDY stock on TipRanks’ Stock Analysis page.